BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BioTech Capital — Shareholder Meeting (November 2006)
30 slides from BTC Health Ltd Registered's shareholder meeting presentation, Nov 23, 2006
Slide 1: Sixth Annual General Meeting
Sixth Annual General Meeting CAPITAL 22 November 2006, Sydney
Slide 2: Outline
Outline {ee} biotech VERE TG CREATE # Overview # Year in review = General markets x Biotechnology sector * Our portfolio = Case studies = Outlook Conclusion
Slide 3: BioTech Capital (BTC)
ae % 232} bi tar 5 lOve CAPITA) Siew BioTech Capital (BTC) BioTech Capital is an active, specialist fund focused on life sciences, that invests in Australian companies seeking to develop and commercialise innovative science and technology
Slide 4: Year in Review
Year in Review Continued strength in global capital markets diminishes investor appetite for risk Available risk capital continues to be directed to junior resources sector Life sciences/biotechnology sector continues to struggle with very few companies maintaining upward momentum in share prices Ho
Slide 5: Markets making new highs
Al, inremrrccrey Markets making new highs USA (Dow Jones Industrial} United Kingdom (FTSE) @ Bloomberg q p25 Japan (Nikkei) Source: www. bloomberg.com
Slide 6: Large biotech stocks doing well
CAPITAL aitnmmmarerses Large biotech stocks doing well CSL Cochlear eet a8 2005 ae 2 05 j ihe ih. i / at i Q - lsh, iii clean seb cna aces ida uni ata Resmed el 500, “8 i 0 “A 8 a 3 (5 i : : / . , | E hit ensues Slit eal tala Source: www. stocknessmonster.com
Slide 7: Small biotech weak
Pcuy To cheat | Small biotech weak Biota Peptech 4 15M 108 an i - cH Fae eal a oillitue leash Source: www. stocknessmonster.com He linet.
Slide 8: Value recognised by some
Value recognised by some GroPep Vision Systems Yn Fuld n a Ie. Ae. 1B. By 25 Zenyth/AMRAD 8 Mayne Pharma © Alb yoo Repeeeweses HE Liss al Bite coo wits ona a toatl A Ae, Source: www. stocknessmonster.com
Slide 9: Relative Performance
Relative Performance Relative Performance Since Listing 120 a a PPD DY PD DH MY HYD DP PPP PH MA AAP HHH PH HSH PF HF SHIP WF SKF GH NHK PPro MY HPF HF HH
Slide 10: Relative Performance
Pcuy To cheat | Relative Performance Relative Performance Since Listing BT 205 1 SX Healthcare index NASDAQ Biotech Index PHFD SF SD DH MM HM P PPP PAH HP SP PSP F CS Woe re Ry oN o” 39 y of We We Se Was FF yah Gi S Poh 2 Sor ew we Wi Pas yf pro FF sFe—* 10
Slide 11: Discount to NTA over time
11 Falling yellow line implies decreasing discount to NTA Discount to NTA over time &
Slide 12: Portfolio companies
Portfolio companies @ Continence + (BIOCOMM reno. sts PHYLOGICA A Ichemia y PRIMABioMed — RT starpharma PACIFIC SYSTEMS 12
Slide 13: Portfolio composition
Phylogica 20% Prima Biomed 1% Starpharma 4% XRT Clinical Cell Culture 15% 5% Alchemia 5% Stem Cell Sciences Continence Control 6% Pacific Knowledge Syst Systems facific Knowledge ‘stems pois ¥ Biocomm 10% 8% 13
Slide 14: Significant milestones achieved
Significant milestones achieved « BTC announces Ms Kathryn Greiner as Chairman » BTC secures new substantial shareholder -— Lazard aw Alchemia (ASX:ACL) Completes pilot scale manufacturing program for synthetic heparin with Dow Chemical Company « Completes major capital raising of $21.6 million and
Slide 15: Significant milestones achieved (cont.)
Cont... « Biocomm « _Investee companies continue to hit milestones, receive grants and raise follow on funding « Licensing business shut down « Focus on maturing existing three investees a Clinical Cell Culture (ASX: CCE) Achieves regulatory approvals for ReCell in Argentina, Australia, Canada « US
Slide 16: Significant milestones achieved (cont.)
, 33} bio! tech Pcuy To cheat | Cont... * Continence Control Systems « Completes first cohort of human implants « Follow up animal studies underway to optimise electrode design « Additional clinical sites being established « Awarded $3.85m Commercial Ready Grant « Pacific Knowledge Systems « Continu
Slide 17: Phylogica milestones
Cont... Phylogica (ASX: PYC) Collaboration with Fox Chase Cancer Centre (USA) Technology licence agreement with Johns Hopkins and Massachusetts General Hospital $2.3m Commercial Ready Grant awarded Collaboration with McComb Foundation to jointly develop molecule for burns injuries Partnership with G
Slide 18: Starpharma milestones
Cont... « Starpharma (ASX:SPL) % Receives US$20m from US National Institute of Health to fund VivaGel development for herpes US subsidiary Dendritic Nanotechnologies (DNT) forms collaboration with National Cancer Institute Raises $15 million through institutional placement VivaGel receives fast-trac
Slide 19: Stem Cell Sciences and XRT milestones
Cont... » Stem Cell Sciences (AIM:STEM) % Licensing agreements with Deltagen and Lexicon Genetics and second distribution deal with Chemicon/Millipore Launch of first product Participant in Euroi2 million ESTOOLS program Technology collaboration with NeuroDiscovery Ltd Establishing high throughput c
Slide 20: Selected Case Studies
Selected Case Studies # XRT « Pacific Knowledge Systems 20
Slide 21: XRT
XRT « High resolution imaging techniques using X-rays « Platform technology with multiple applications » Life sciences * Non-destructive industrial testing # Diamond inspection tools « At commercialisation stage of development - sales, licensing, partnering occurring now x Re-focused growth strategy
Slide 22: XRT cont
XRT cont _ 22
Slide 23: XRT cont
XRT cont Zebra fish embryo Looking for developmental differences we Beer jar —n _mdttemal organ eo development MUTANT Volume rendering & rotational views. of . surface following temegraphie reconstruction MRT Mutant vs normal zebra fish nce Sagan fiuting Be 8.0. Map ages Eon B88, Mare EE 23
Slide 24: XRT cont
XRT cont jet using the XuM ve iM Tamegraphy. 24
Slide 25: Pacific Knowledge Systems
Pacific Knowledge Systems « Informatics platform technology « Labwizard — software tool for pathology labs « Customises and adds value to the processing of pathology results « Other applications identified broadening product range * “per click”revenue model 25
Slide 26: Pacific Knowledge Systems
Pacific Knowledge Systems w Disease Management Programs # Patient recall service Health Data Mining « Big pharma Bone Mineral Density Knowledge Bases # Working with leading specialists and groups Joint Ventures # Medical and non-medical applications 26
Slide 27: Pacific Knowledge Systems' LabWizard
Pacific Knowledge Systems’ LabWizard Lat information Secten PATHOLOGY REQUEST iGiechern fifi: ras te. VNVALIOAT BE REST | Request for LabWinard : LA ion | interpreter Server = ‘Ubvew actu aatubal = » Hovde peenitnntiies & ' '. : Labvvinard Validiater g ~ Seictated | Frnt nen ee | Pore teradigpee Den
Slide 28: Pacific Knowledge Systems
Pacific Knowledge Systems « Continue to grow revenues in Australia from core products « Expand offshore growth opportunities « Expand range of applications « Core health applications in pathology, pharmaceutical, diagnostics, quality control & logistics « Non-health via funded joint ventures * Likel
Slide 29: Outlook
, 33} bio! tech Pcuy To cheat | Outlook « Listings/Exits « Potential for listing 1-2 of our unlisted investees over next 12 months » Opportunity to exit listed holdings will be evaluated as opportunities arise » New Investments » Continuously evaluating new opportunities with current areas of intere
Slide 30: Why invest in BTC?
Why invest in BTC? w Diversified portfolio in terms of stage of development and sector Access to expertise and networks of leading scientists when assessing investment opportunities Retail investors get access to unlisted Australian biotech companies Trading at a discount to underlying NTA 30
BioTech Capital — Shareholder Meeting (November 2006) on 6ix